Kestra Advisory Services’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
Other funds holding IBRX
Kestra Advisory Services's IBRX Position: Q3 2026 in Review
Kestra Advisory Services increased its ImmunityBio (IBRX) stake by 4.3% in Q3 2026, buying an estimated $38.2K and bringing the position to 115,410 shares worth $1.09M. The position accounts for ﹤0.01% of the portfolio, ranked #1904.
Kestra Advisory Services first reported a position in IBRX in Q2 2023 and has held it in 14 quarters since. 321 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.
- Kestra Advisory Services held 115,410 shares of ImmunityBio worth $1.09M as of Q3 2026.
- Kestra Advisory Services bought 4,780 ImmunityBio shares in Q3 2026, an estimated $38.2K.
- ImmunityBio made up ﹤0.01% of Kestra Advisory Services's portfolio in Q3 2026, its #1904 holding.
- Kestra Advisory Services first reported a position in ImmunityBio in Q2 2023 and has held it in 14 quarters since.
- 321 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.
Based on Kestra Advisory Services's 13F filing for Q3 2026, filed 2 Nov 2026.